StockIQStockIQ.tech

Veeva Systems Inc. (VEEV) Stock Analysis

--

Free AI-powered analysis and research for Veeva Systems Inc. stock

Sector: Healthcare

VEEV snapshot

Data as of 3 Nov 2026 close. Updated daily.

Last close
304.25 USD (-0.90%)
52-week range
148.05 – 325.99
Position in range
88%
1-year change
+3.9%
Market cap (USD)
$49.3B
P/E (trailing)
51.4
RSI (14-day)
53
vs 200-day average
+44.8%
MACD
Below signal line
StockIQ score: 76/100 · Strongly positive signals

Veeva Systems Inc. scores 76/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 88% of its 52-week range, up 3.9% over the past year. Latest reported figures show a profit margin of 29.3%, return on equity of 14.4% and revenue growth of +17.6%.

What is driving the score
  • RSI Neutral: +5
  • Mixed Trend: +2
  • MACD Bearish: -8
  • High P/E (51.4): -10
  • Strong Revenue Growth (17.6%): +8
  • Excellent Profit Margin (29.3%): +10
  • Low Debt (0.02 D/E): +8
  • Strong Liquidity (5.46 Current Ratio): +8
  • High P/B (6.92): -5
  • Strong Long-term Uptrend: +8
  • Up Over 1 Year (+3.9%): +3
  • Low Volume (0.4x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full VEEV report

Veeva Systems Inc. (VEEV) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze VEEV Now β†’

πŸ“° Latest Update

Why Veeva Systems (VEEV) Dipped More Than Broader Market Today

Veeva Systems (VEEV) saw a decline of 1.9% to $307.00, underperforming the S&P 500's loss of 0.51%. Despite this dip, the stock has increased by 14.5% over the past month, outperforming the Medical sector and the S&P 500. Investors are keenly awaiting the upcoming earnings release, with projected EPS of $2.33 and revenue of $933.79 million, reflecting significant year-over-year growth. Veeva currently holds a Zacks Rank of #3 (Hold).

Read full article β†’

History

People also watch

MRK
Merck & Co. Inc.
--
VRTX
Vertex Pharmaceuticals Inc.
--
BMY
Bristol-Myers Squibb Company
--
KIDS
OrthoPediatrics Corp.
--
INNV
InnovAge Holding Corp.
--